Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an announcement.
Chimeric Therapeutics has secured a $1.785 million advance from Radium Capital, drawing on its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and general working capital. The facility, backed by the expected tax offset from the Australian Taxation Office and repayable after receipt of the FY26 incentive, provides the company with non-dilutive funding to sustain progress across its CAR T and NK cell therapy programs, including ongoing phase 1/2 studies in gastrointestinal, neuroendocrine and brain cancers.
The most recent analyst rating on (AU:CHM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is a Melbourne-based, clinical-stage cell therapy company and a leading Australian player in oncology-focused cell therapies. The company is developing a diversified portfolio of first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies targeting multiple cancer indications, with four programs already in clinical stages.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.63M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.